ATTO (Attovia Therapeutics Inc.) stock: $15.27, $697.1M market cap, $380.2M cash, $316.9M EV, $738.1M fully diluted market cap. Next expected readout: Jul-28. Lead program: ATTO-1310 (Chronic Pruritus of Unknown Origin), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
Attovia Therapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company headquartered in San Carlos, California and focused on research and development of therapeutic products in the fields of immune-mediated diseases. The Company was incorporated in the State of Delaware on December 16, 2022 and subsequently commenced principal operations in June 2023.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Named in the 10-Q risk factors as one of the company's three product candidates; no indication, stage, modality, or target disclosed in the excerpts. Company has completed no clinical trials to date; candidates are in preclinical or clinical development.
ATTO-2306
Stage not disclosed · Active
Target IL-13/IL-31
Status note Named in the 10-Q risk factors as one of the company's three product candidates; no indication, stage, modality, or target disclosed in the excerpts. Company has completed no clinical trials to date; candidates are in preclinical or clinical development.
ATTO-1091
Stage not disclosed · Active
Target TL1A/IL-23/α4β7
Indications
Ulcerative Colitis (UC)(Phase 1)
Status note Named in the 10-Q risk factors as one of the company's three product candidates; no indication, stage, modality, or target disclosed in the excerpts. Company has completed no clinical trials to date; candidates are in preclinical or clinical development.
Per-asset detail extracted from the 10-Q filed 2026-09-02. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.